Logo image of PCRX.CA

PHARMACORP RX INC (PCRX.CA) Stock Fundamental Analysis

Canada - TSX Venture Exchange - TSX-V:PCRX - CA71714X1050 - Common Stock

0.42 CAD
+0.01 (+1.2%)
Last: 12/8/2025, 7:00:00 PM
Fundamental Rating

2

Taking everything into account, PCRX scores 2 out of 10 in our fundamental rating. PCRX was compared to 18 industry peers in the Consumer Staples Distribution & Retail industry. No worries on liquidiy or solvency for PCRX as it has an excellent financial health rating, but there are worries on the profitability. PCRX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PCRX had negative earnings in the past year.
PCRX had a positive operating cash flow in the past year.
PCRX.CA Yearly Net Income VS EBIT VS OCF VS FCFPCRX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -500K -1M -1.5M

1.2 Ratios

PCRX has a Return On Assets of 0.48%. This is in the lower half of the industry: PCRX underperforms 66.67% of its industry peers.
Looking at the Return On Equity, with a value of 0.63%, PCRX is doing worse than 66.67% of the companies in the same industry.
Industry RankSector Rank
ROA 0.48%
ROE 0.63%
ROIC N/A
ROA(3y)-14.02%
ROA(5y)N/A
ROE(3y)-14.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PCRX.CA Yearly ROA, ROE, ROICPCRX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -5 -10 -15 -20

1.3 Margins

PCRX's Profit Margin of 1.08% is on the low side compared to the rest of the industry. PCRX is outperformed by 66.67% of its industry peers.
The Gross Margin of PCRX (39.77%) is better than 83.33% of its industry peers.
Industry RankSector Rank
OM N/A
PM (TTM) 1.08%
GM 39.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PCRX.CA Yearly Profit, Operating, Gross MarginsPCRX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 20 -20

More info and screens

7

2. Health

2.1 Basic Checks

PCRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
PCRX has more shares outstanding than it did 1 year ago.
PCRX has a worse debt/assets ratio than last year.
PCRX.CA Yearly Shares OutstandingPCRX.CA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M 80M 100M
PCRX.CA Yearly Total Debt VS Total AssetsPCRX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

PCRX has an Altman-Z score of 4.94. This indicates that PCRX is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 4.94, PCRX belongs to the best of the industry, outperforming 94.44% of the companies in the same industry.
The Debt to FCF ratio of PCRX is 2.81, which is a good value as it means it would take PCRX, 2.81 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 2.81, PCRX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
PCRX has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of PCRX (0.13) is better than 100.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF 2.81
Altman-Z 4.94
ROIC/WACCN/A
WACC7.74%
PCRX.CA Yearly LT Debt VS Equity VS FCFPCRX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

A Current Ratio of 2.53 indicates that PCRX has no problem at all paying its short term obligations.
The Current ratio of PCRX (2.53) is better than 100.00% of its industry peers.
PCRX has a Quick Ratio of 1.79. This is a normal value and indicates that PCRX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.79, PCRX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.53
Quick Ratio 1.79
PCRX.CA Yearly Current Assets VS Current LiabilitesPCRX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 5M 10M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for PCRX have decreased by -5.98% in the last year.
EPS 1Y (TTM)-5.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%334.83%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PCRX.CA Yearly Revenue VS EstimatesPCRX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 1M 2M 3M 4M 5M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

Industry RankSector Rank
PE N/A
Fwd PE N/A
PCRX.CA Price Earnings VS Forward Price EarningsPCRX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PCRX indicates a rather expensive valuation: PCRX more expensive than 88.89% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, PCRX is valued a bit more expensive than 72.22% of the companies in the same industry.
Industry RankSector Rank
P/FCF 47.5
EV/EBITDA 130.81
PCRX.CA Per share dataPCRX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.05 0.1 0.15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PCRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHARMACORP RX INC

TSX-V:PCRX (12/8/2025, 7:00:00 PM)

0.42

+0.01 (+1.2%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupConsumer Staples Distribution & Retail
GICS IndustryConsumer Staples Distribution & Retail
Earnings (Last)11-29 2025-11-29
Earnings (Next)04-20 2026-04-20
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners10.67%
Ins Owner ChangeN/A
Market Cap73.11M
Revenue(TTM)17.60M
Net Income(TTM)189.60K
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.15
P/FCF 47.5
P/OCF 45.48
P/B 2.44
P/tB 9.14
EV/EBITDA 130.81
EPS(TTM)0
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.01
FCFY2.11%
OCF(TTM)0.01
OCFY2.2%
SpS0.1
BVpS0.17
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.48%
ROE 0.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 1.08%
GM 39.77%
FCFM 8.74%
ROA(3y)-14.02%
ROA(5y)N/A
ROE(3y)-14.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF 2.81
Debt/EBITDA 7
Cap/Depr 8.65%
Cap/Sales 0.39%
Interest Coverage N/A
Cash Conversion 293.95%
Profit Quality 811.87%
Current Ratio 2.53
Quick Ratio 1.79
Altman-Z 4.94
F-Score6
WACC7.74%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.14%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%334.83%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-174.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y122.73%
FCF growth 3Y518.15%
FCF growth 5YN/A
OCF growth 1Y124.06%
OCF growth 3Y529.96%
OCF growth 5YN/A

PHARMACORP RX INC / PCRX.CA FAQ

What is the ChartMill fundamental rating of PHARMACORP RX INC (PCRX.CA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to PCRX.CA.


What is the valuation status of PHARMACORP RX INC (PCRX.CA) stock?

ChartMill assigns a valuation rating of 0 / 10 to PHARMACORP RX INC (PCRX.CA). This can be considered as Overvalued.


How profitable is PHARMACORP RX INC (PCRX.CA) stock?

PHARMACORP RX INC (PCRX.CA) has a profitability rating of 1 / 10.


What is the financial health of PHARMACORP RX INC (PCRX.CA) stock?

The financial health rating of PHARMACORP RX INC (PCRX.CA) is 7 / 10.